CD8A and Miyoshi myopathy: Relevance to T-cell–directed therapies in MM has also been probed by assessing bispecific antibody-elicited CD8+ T-cell activity and cytotoxicity, and analysis of BM and peripheral T-cell populations in patients with MM.